COMy 2019 | How are treatment practices changing in Waldenström’s?

Name: How are treatment practices changing in Waldenström’s?
Uploaded: 2019-05-17T00:00:00.000Z
Duration: 1 min 18 s
Description: Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses changing practices in Waldenström’s Macroglobulinemia, including novel targets for therapy. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Steven Treon • 17 May 2019

COMy 2019

Rare Diseases Waldenström’s Macroglobulinemia Bortezomib Ibrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses changing practices in Waldenström’s Macroglobulinemia, including novel targets for therapy. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.